Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, David T. Rubin et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled TrialsAxel Dignaß, Walter Reinisch, Wolfgang Stremmel et al.|Clinical Gastroenterology and Hepatology|2023Cited by 4